BR1015-A Pharmacokinetics and Safety Study in Healthy Volunteers

Phase 1, randomised, open-label trial of fimasartan + indapamide in essential hypertension (2 arms), sponsored by Boryung. Primary endpoints: Area Under the Curve to the last measurable concentration of Fimasartan at 48 hours, Area Under the Curve to the last measurable concentration of Indapamide at 72 hours and 2 more. Planned start Apr 2026; status: not yet recruiting.